The Atypical Commissioner Turns Out Well: Hamburg Receives Mostly Fond Farewell
This article was originally published in The Pink Sheet Daily
Margaret Hamburg’s public health, as opposed to academic medicine, background was off-putting to some in pharma initially, but she’ll leave the agency in March with high drug approval numbers and significant praise for new initiatives such as the breakthrough therapy program.
You may also be interested in...
Hamburg’s Public Farewell Includes Rallying Cry For FDA Power
Outgoing commissioner gives forceful defense of the agency’s regulatory authority and warns that lowering drug approval standards would damage both patients and industry.
FDA’s Hamburg Says EMA Could Be Model For Global Regulatory Coalition
Outgoing commissioner urges authorities to move away “from an outdated paradigm of only working in our own jurisdiction” in speech at European Medicines Agency’s 20th anniversary meeting.
Life After White Oak: Hamburg’s Predecessors Offer Glimpse At Where Pharma Might See Her Again
In interviews with “The Pink Sheet,” the last half-dozen FDA commissioners discuss crafting policy on Capitol Hill, building start-up biotechs, consulting and serving on industry boards.